Table 1.

Baseline characteristics and treatment of KTRs total population. Comparison between KTRs who were transferred to the Hotel Salut (Health Hotel, HH) and those who were discharged directly from the Hospital

	Total population (n = 28)	Transferred to HH (n = 12)	Discharged from the Hospital (n = 16)	P‐value
Age	52.50 [46.25‐68]	48.50 [43.75‐57.25]	58 [47.25‐72.75]	.110
Sex (% males)	18/28 (64.3%)	7/12 (58.3%)	11/16 (68.8%)	.698
Time from transplant	56.46 [22.01‐125‐45]	42.56 [12.21‐74.75]	65.15 [26.11‐134.92]	.423
Baseline immunosuppression
TAC + MPA	14/28 (50.0%)	5/12 (41.7%)	9/16 (56.3%)	.240
TAC + mTORi	9/28 (32.1%)	6/12 (50.0%)	3/16 (18.8%)
Other	5/28 (17.9%)	1/12 (8.3%)	4/16 (25.0%)
Creatinine at baseline (mg/dL)	1.55 [1.15‐2.18]	1.93 [1.44‐2.54]	1.29 [1.13‐2.10]	.093
Positive PCR swab (%yes)	23/28 (82.1%)	9/12 (75.0%)	14/16 (87.5%)	.624
Symptoms (%yes)
Fever	26/28 (92.9%)	10/12 (83.3%)	16/16 (100.0%)	.175
Cough	18/28 (64.3%)	9/12 (75.0%)	9/16 (56.3%)	.434
Dyspnea	9/28 (32.1%)	2/12 (16.7%)	7/16(43.8%)	.223
Gastrointestinal	7/28 (25.0%)	2/12 (16.7%)	5/16 (31.3%)	.662
Dysgeusia	3/28 (10.7%)	1/12 (8.3%)	2/16 (12.5%)	1
Pneumonia	25/28(95.3%)	9/12 (75.0%)	16/16 (100.0%)	.067
AKI	19/28 (67.9%)	9/12 (75.0%)	10/16 (62.5%)	.687
Need of dialysis	3/28 (10.7%)	0/12 (0.0%)	3/16 (18.8%)	.238
Treatment
Lopinavir/Ritonavir	24/28 (85.7%)	9/12 (75.0%)	15/16 (93.8%)	.285
Hydroxicloroquine	27/28 (96.4%)	12/12 (100.0%)	15/16 (93.8%)	1
Azithromycin	27/28 (96.4%)	11/12 (91.7%)	16/16 (100.0%)	.429
Tocilizumab	18/28 (64.3%)	6/12 (50.0%)	12/16 (75.0%)	.243
Steroids (bolus)	8/28 (28.6%)	3/12 (25.0%)	5/16 (31.3%)	1
ICU Admission	8/28 (28.6%)	3/12 (25.0%)	5/16 (31.3%)	1
Death	5/28 (17.9%)	0/12 (0.0%)	5/16 (31.3%)	.053
Length of stay
At the Hospital	12.50 [8.25‐19.50]	8 [4.25‐13.50]	15.50 [12‐25.50]	.001
At the Hotel	/	9.50 [6.50‐12.50]	/
Total	18 [13‐24]	19.00 [16.25‐24]	15.50 [12‐25.50]	.631